McCarter & English, LLP | Contents of this website may contain attorney advertising. | Results may vary depending on your particular facts and legal circumstances.
Represented a group of high net worth investors in their acquisition of a controlling block of preferred stock of a clinical stage biotechnology company whose securities are registered on Nasdaq Capital Market. The aggregate purchase price was $11.2 million.
The McCarter & English, LLP website is for informational purposes only. We do not provide legal advice on this website. We can provide legal advice only to our clients in specific inquiries that they address to us. If you are interested in becoming a client, please contact us, but do not send any information about your specific legal question. We cannot serve as your lawyers until we establish an attorney-client relationship, which can occur only after we follow procedures within our firm and after we agree to the terms of the representation.
Accept Cancel